Biweekly oxaliplatin and irinotecan chemotherapy in advanced gastric cancer. A first-line multicenter phase II trial of the Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT).

Wöll, E; Kühr, T; Eisterer, W; Gattringer, K; Greil, R; Zabernigg, A; Hilbe, W; Thaler, J; Anticancer Res. 2008; 28(5B):2901-2905

Is Chemoendocrine Treatment without Alternative?

Greil, R; Breast Care (Basel). 2008; 3(4): 231-235.

Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.

Heinrich, E; Schally, AV; Buchholz, S; Rick, FG; Halmos, G; Mile, M; Groot, K; Hohla, F; Zarandi, M; Varga, JL; Prostate. 2008; 68(16):1763-1772

The Inverse Correlation of Regulatory T Cells and Time to Initial Treatment in Chronic Lymphocytic B-Cell Leukemia

Weiss, L; Melchardt, T; Grabmer, C; Egle, A; Tinhofer, I; Greil, R BLOOD. 2009; 114(22): 510-510.

FINAL RESULTS OF ORAL FLUDARABINE WITH CONCOMITANT SUBCUTANEOUS ALEMTUZUMAB IN RELAPSED/REFRACTORY B-CHRONIC LYMPHOCYTIC LEUKAEMIA (B-CLL): THE FLUSALEM STUDY

Egle, A; Melchardt, T; Pleyer, L; Tinhofer, I; Lang, A; Keil, F; Thaler, J; Gunsilius, E; Fridrik, M; Greil, R HAEMATOL-HEMATOL J. 2009; 94: 140-140.

The REVLIRIT CLL5 AGMT Study – a Phase I/II Trial Combining Fludarabine/Rituximab with Escalating Doses of Lenalidomide Followed by Rituximab/Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL): Results of a Planned Interim Analysis

Egle, A; Steurer, M; Melchardt, T; Stoll, M; Greil, R BLOOD. 2009; 114(22): 1341-1342.

Neoadjuvant chemoradiation therapy with capecitabine (X) plus cetuximab (C), and external beam radiotherapy (RT) in locally advanced rectal cancer (LARC): ABCSG trial R03

Eisterer, WM; De Vries, A; Oefner, D; Greil, R; Rabl, H; Tschmelitsch, J; Schmid, R; Kapp, K; Zehentmayr, F; Thaler, J J CLIN ONCOL. 2009; 27(15):

ADDITION OF ZOLEDRONIC ACID (ZOL) TO ADJUVANT ENDOCRINE THERAPY IMPROVES DISEASE-FREE (DFS) AND RECURRENCE-FREE SURVIVAL (RFS) IN PREMENOPAUSAL WOMEN WITH HORMONE-RESPONSIVE EARLY BREAST CANCER (HREBC): MULTIVARIATE ANALYSES OF THE AUSTRIAN BREAST AND COLORECTAL CANCER STUDY GROUP 12 (ABCSG-12) TRIAL

Gnant, M; Mlineritsch, B; Schippinger, W; Luschin-Ebengreuth, G; Poestlberger, S; Menzel, C; Jakesz, R; Kubista, E; Marth, C; Greil, R ANN ONCOL. 2009; 20: 30-30.

Improved outcome following reduced-intensity conditioning for second allogeneic stem cell transplantation

Nachbaur, D; Auberger, J; Clausen, J; Lindner, B BONE MARROW TRANSPL. 2009; 43: S285-S286.

Reduced-intensity HLA-haplo-identical stem cell transplantation with post transplantation cyclophosphamide in patients with advanced haematological malignancies

Nachbaur, D; Auberger, J; Muehlmann, R; Kircher, B; Clausen, J BONE MARROW TRANSPL. 2009; 43: S286-S286.